Beh<;et's Disease (BD) is a multisystem inflammatory disorder characterized by recurrent oral and genital ulcerations with uveitis. Clinical feature s are the only diagnostic and follow up parameters and there is no unique laboratory test to indicate both diagnosis and disease activity. We studied urinary neopterin levels by using high performance liquid chromatography in 21 consecutive patients with Beh<;:et's Disease in clinically active (n = 13) and inactive (n = 8) phase of the disease and in 14 healthy controls to investigate the correlation between this immunologic parameter and the disease status. In comparison to inactive phase, significantly higher urinary neopterin levels were found in active period (p<O.05). Mean urinary neopterin levels were 210.83 ± 157.19 vs 138.85 ± 56.99 I-imol neopterin/ mol creatinine in active and inactive t1hase respectively (p<O.05). There was no significant difference between inactive phase and control values. In only 2 patients, both active and inactive phase urine neopterin levels could be measured in the same individual and increased neopterin levels were also determined in the active phase of disease. In conclusion, urinary neopterin levels were found to be elevated in active period and can be considered as an active phase marker in BD. Larger study groups with own controls of BD patients and other vasculitic disease controls are required before the final judgement.
Introduction
Beh<;:et's Disease (BD) is a multisystem disorder characterized by vasculitis. It was first described by Hulusi Beh<;:et in 1937, and consists of recurrent oral and genital ulceration with uveitis l. Later, It was realized that there may be some other systemic manifestation of the disease at the time of diagnosis, including vascular lesions, central nervous system involvement, arthritis, pulmonary and gastrointestinal involvement. Viruses, streptococcal infection, autoimmune mechanisms, endothelial cell dysfunction and enviromental toxic agents have all been § Author to whom correspondence should be addressed.
Pteridines / Vol. 6 / No.2 implicated in the ethiopathogenesis of BD but no definite cause has yet been identified. However, an immunologic alteration seems to be strongly possible in the pathogenesis of the disease. Recent evidence indicates that immune responses are mainly controlled by supressor and helper T -cells and that alterations in such immunoregu1atory systems may be involved in the pathogenesis of various autoimmune conditions including BD.
Combination of certain clinical features (diagnostic criterias) have been used in the diagnosis and follow up of BD2. But there is no specific biomarker for supporting the diagnosis of this syndrome and using as a follow up laboratory parameter. Neopterin derived from guanosine triphosphate is a me-tabolite of dihydroneopterin-triphosphate. Neopterin is mainly produced by macrophages upon stimulation with interferon gamma from activated Tlymphocytes J • Elevated neopterin levels are associated with a variety of diseases involving inflammatory disorders associated with the activation of cell mediated immunity. Increased concentrations have been described in allograft rejections, viral infections, infections by bacteria and intracellular protozoa, autoimmune disorders, graft-versus-host diseases, and variety of malignant disorders 4 .
5
• These observations prompted us to study urinary neopterin levels in a group of patients with BD in order to investigate a correlation with disease activity.
Material and Methods
Twenty-one consecutive patients with BD, in whom the duration of the disase ranged from 1 to 12 years (median 3 yr.), were examined. Urine samples were collected from 13 patients with BD in active phase (6 women and 7 men, ages 20-40) and 8 patients in inactive phase (3 women, 5 men, ages 20-35), when they came to the outpatient clinic in Hacettepe University Hospital. Fourteen healthy controls (7 females and 7 males, ages 21-55) served as controls. Patients and controls were not significantly different regarding age and body mass.
The activation of disease was determined by a standardized activity evaluation criteria including presence of recurrent oral and/or genital ulcers. erythema nodosum, uveitis, trombophlebitis, arthritis. During the sampling time some patients have continued to receive Colchicine, at a dose of 0.5 mg/day orally, which has been given to control muco-cutaneous manifestations of the disease since the diagnosis was made (Table 1) . Urinary neopterin levels were measured by using high performance liquid chromatography (HPLC) and the values of the phases of disease and of controls were compared.
We obtained first morning urine samples from all of the studied subjects and stored at -36°C and kept from direct light until analysis. Urinary neopterin was measured by HPLC as described previously5.
A model 510 HPLC pump, WISP 710 automatic sample injector controlled by SIM and equipped with a model 470 fluorescence detector (Waters Associates, Milford, MA, USA) were used. Peak areas were monitored by NEC 80386 SX PLUS data system. Then procedure of HPLC analysis is as follows:
After diluting 200 f.ll of untreated urine specimens with 1 ml mobile phase (7 The qualification and quantification of chromotograms were achieved by using the external standard method (neopterin, Sigma, USA). By dilutings stock solution of neopterin (500 /lgl1O ml) with distilled water, neopterin standard solutions (120, 360, 1200, 2400, 4800, 6000 nglm1)were prepared and a standard curve was drawn (Fig. 1) . Linear regression analysis was performed and the linear equation was calculated as: y=0.0066+0.001x (r2= I). The retention time and peak area of neopterin were checked with a neopterin standard for each day of analysis. Within run and between run precision of the method were less than } 0% and recovery was about 93%. Neopterin concentrations were expressed as Ilmo} neopterin/mol creatinine. A Shimadzu UV 160 Spectrophotometer (Shimadzu, Tokyo, Japan) was used for the determination of the creatinine levels. They were measured at 520 nm by a spectrophotometric method using alkaline-picrate reaction 6 • Statistical comparison between active and inactive phase values and controls was performed by the Mann Whitney-U test.
Results
Urinary neopterin levels of 21 patients with Beh<; et's Disease and 14 healthy volunteers were studied using HPLC with fluorescence detector. The results were shown in Table 2 .
Urinary neopterin levels were found to be significantly higher in patients with active disease than those with inactive disease and controls. As compared with the patients in inactive phase and control groups respectively, mean urinary neopterin level in active stage of the disease was 210.83 ± 157.19/lmol neopterin/ mol creatinine vs 138.85 ± 56.99, 124.89 ± 43.59 Ilmol neopterin/ mol creatinine (p<0.05). We found that urinary neopterin levels in the active stage were significantly higher than in the control and inactive phase group (p<0.05). The difference between patients with inactive disease and healthy controls, however, was not statistically significant. Both active and inactive phase urine neopterin levels could be measured in 2 patients and the same correlation between increased neoplerin levels and disease activity was also observed. The characteristics of the patients and their neopterin levels were shown in Table 1 .
Discussion
The production of neopterin is closely related to the activation of cellular immunity. In vitro, it has been found that the activation of human peripheral blood mononuclear cells with allogens, virally or chemically modified autologous cells and with mitogenic lectins is associated with neopterin production 7 • Whenever these cells are stimulated by interferon-gamma (IFN-y) via activated T lymphocytes during immune response they also release neopterin into the medium 3 • In vito, it was shown neopterin levels in biological fluids were increased in the disease related with activation of cellular immune system including various malignancies', viral infections 9 .
10 acute graft rejectionll and also autoimmune diseases
Recently, in the light of many studies it has been found that neopterin is a valuable biomarker in follow up allograft recipients and in the detection of acute graft rejection after transplantation II . 13, in the monitoring of clinical activity in inflammatory disease l '
and in predicting the clinical outcome of HIV patients l 5 • More recently, it has been shown that higher neopterin concentration in urine and serum of HIV-l seropositive patients were significantly associated with progression to AIDS and with occurrence of AIDS-associated death l6
• From the data it is evident that particularly activated T-Iymphocytes and macrophages playa major role in the pathogenesis of diseases.
As mentioned before Beh<;et's syndrome is a chronic inflammatory multisystem condition of unknown etiology and several mechanisms may be responsible for this disorder. However, at present, an immunologic pathogenesis is strongly suggested. Autoantibodies have been identified against oral mucosal membranes 17. 18. 19. Specific cell mediated immunity to mucosal antigens has been demonstrated by inhibition of leucocyte migration 20 and lymphocyte cytotoxicity for oral epithelial cells 21 •
Other authors have, however, described disturbances in local defences namely in the salivary immunoglobulin secretory system and abnormalities of coagulation and fibrinolytic systems, that may also be pathogenetic ally important 22
• Kansu et al. have found reduced numbers of T-helper and Tsuppressor cells, but no changes in T -helperff suppressor ratio and elevated number of B-cells 23 •
In spite of these extensive studies, it is still obscure whether T cell changes are primary to the disease pathogenesis and/or secondary to another causative agents or mechanisms. However, disregulation of T-cell immune system is widely accepted as pathogenetic mechanism in BD.
We investigated the association of neopterin and BD in a small group of patients because enhanced neopterin levels in biological fluids especially in urine indicate activation of cellular immunity.
Urinary neopterin excretion was above the upper normal limit in a considerable proportion of our series. The number of patients with raised neopterin excretion was clearly related to the disease activity. This preliminary stuch fails to showed a significant elevation of neopterin in all BD with active disease compared with control groups. However, the number of patients is not sufficient to draw a final conclusion. In this study, an increased urine neopterin level measured by HPLC correlated with the disease activity in BD, Among the patients with active disease, high neopterin concentrations of two patients slightly diminished when the active disease lesions disappeared by treatment.
The highest neopterin level (683.60 jJmol/mol creatinine) was determined in one pregnant patient with active BD. This may reflect the combined effect of her pregnancy and of BD on neopterin levels. As previously described, elevated neopterin levels were observed in association with activated cellmediated immunity during the last trimester of pregnancy24.
In conclusion our results suggest that urinary neopterin measurements in BD as an activity parameter of disease may provide a valuable information of the status of the patient and to make a decision in the treatment, but also they indicate that activated T-lymphocytes and macrophages playa role in the pathogenesis of Beh<;et's Disease. Further studies on neopterin's role in the monitoring of cePteridines / Vol. 6 / No.2 llular immune system reactions during the natural history of BD are needed.
